标题：浆液性卵巢癌患者的斯钙素2表达水平及其与预后的关系

      作者：吴文娟 1，陈历排 1，张东辉 2，高春辉 3    广州医科大学附属肿瘤医院妇科肿瘤外科 1、病理科 2、重症医学科 3，广东 广州 510095

      卷次： 2023年34卷15期

      【摘要】 目的 基于公共数据库分析斯钙素 2 (STC2)在泛癌中的作用，并在浆液性卵巢癌组织中验证STC2的表达水平及其与预后的相关性。方法 应用生物信息学方法对癌症基因组图谱(TCGA)及GTEx数据库中转录组数据进行分析，分析STC2 mRNA在泛癌中的表达差异及其与免疫、预后等的关系。收集病理确诊为卵巢浆液性癌102例及正常卵巢组织26例，采用免疫组织化学染色检测癌组织及正常组织中STC2的表达水平，分析STC2的表达水平与浆液性卵巢癌患者临床病理特征、预后的关系。结果 STC2 mRNA在多种癌种中存在差异表达，并与预后相关，提示STC2在肿瘤的发生发展中可能发挥较为重要的作用。尤其在浆液性卵巢癌组织中，STC2的表达率为32.35%，明显高于正常组织中的 3.85%，差异有显著统计学意义(P=0.002 3)。Cox回归分析结果显示，卵巢癌组织中 STC2低表达的患者预后更差 (P<0.001)，这与 STC2在公共数据库中的探针 203438_at (P=0.022)以及203439_s_at (P=0.006 4)中的预后意义一致，说明STC2是卵巢癌患者预后相关的风险因素。结论 STC2可作为高级别浆液性卵巢癌患者的预后因子，为其发病机制及靶向治疗的研究提供依据。
      【关键词】 卵巢癌；斯钙素2；生物信息学；免疫组化；预后
      【中图分类号】 R737.31 【文献标识码】 A 【文章编号】 1003—6350（2023）15—2181—06

Expression level of STC2 in patients with serous ovarian cancer and its relationship with prognosis.WU Wen-juan 1, CHENLi-pai 1, ZHANG Dong-hui 2, GAO Chun-hui 3.
Department of Gynecological Oncology 1, Department of Pathology 2,Department of Critical Care Medicine 3, Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Guangzhou 510095, Guangdong, CHINA
【Abstract】 Objective To analyze the role of Stanniocalcin 2 (STC2) in Pan-cancer based on public databases,and to verify the expression of STC2 and its relationship with prognosis in serous ovarian cancer. Methods The tran-scriptome data in the Cancer Genome Atlas (TCGA) and GTEx database were analyzed by bioinformatics methods to in-vestigate the expression difference of STC2 mRNA in Pan-cancer and its relationship with immunity and prognosis. Sam-ples were collected from 102 patients pathologically diagnosed as serous ovarian cancer and 26 healthy subjects, andthe expression level of STC2 in the cancer and normal tissues was evaluated via immunohistochemical staining. Thecorrelation between STC2 expression and clinicopathological features, prognosis of serous ovarian cancer was analyzed.Results STC2 mRNA was differentially expressed in a variety of cancers and was related to the prognosis, indicatingthat STC2 may play an important role in the occurrence and development of tumors. In serous ovarian cancer tissue, theexpression rate of STC2 was up to 32.35%, which was significantly higher than 3.85% in normal tissues (P=0.002 3).Cox regression analysis showed that patients with low expression of STC2 in serous ovarian cancer had a poor prognosis(P<0.001). This was consistent with the prognostic significance of STC2 in public database with probe 203438_at and203439_s_at, indicating that STC2 was a risk factor for the prognosis of ovarian cancer. Conclusion STC2 can be usedas an independent influencing factor for the prognosis of high-grade serous ovarian cancer, providing a basis for thestudy of the pathogenesis and targeted treatment of ovarian cancer.
      【Key words】 Ovarian cancer; STC2; Bioinformatics; Immunohistochemistry; Prognosis